Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer J. 2019 Jan-Feb;25(1):45–53. doi: 10.1097/PPO.0000000000000355

Table 1:

FDA approved agents in multiple myeloma in 2018.

Drug Class Target
Melphalan Alkylating agent DNA
BiCNU Alkylating agent DNA
Cyclophosphamide Alkylating agent DNA
Doxorubicin Anthracyclin DNA
Thalidomide IMid Cereblon/E3 ubiquitin ligase complex
Lenalidomide IMid Cereblon/E3 ubiquitin ligase complex
Bendamustine Alkylating agent Purine analog DNA
Bortezomib Reversible proteasome Inhibitor Proteasome 20s unit
Ixazomib Reversible proteasome Inhibitor proteasome 20s unit
Carfilzomib Irreversible Proteasome Inhibitor proteasome 20s subunit inhibition
Daratumumab Moncolnal antibody CD38
Pomalidomide IMid Cereblon/E3 ubiquitin ligase complex
Elotuzumab Monoclonal antibody CS1
Panobinostat HDCA inhibitor Pan-HDAC